What does it mean to “win” a launch?

​Hear from NNIT, Beghou, and Sage Advisors in this interactive panel discussion that will challenge traditional definitions of launch success and explore the diverse perspectives that shape organizational decision-making.

For many emerging biopharmaceutical companies, success is often measured by achieving key development milestones such as positive clinical data, a successful NDA/BLA submission, regulatory approval, or manufacturing readiness. Yet industry data consistently demonstrates that many organizations struggle to meet launch expectations even after achieving these milestones. Why?

The reality is that “winning” means different things to different stakeholders.

For Clinical Development teams, success may be advancing a program through key milestones. Regulatory leaders may define success as achieving approval without delays.

Manufacturing and Supply Chain organizations focus on reliable product availability and uninterrupted patient access. Commercial teams evaluate success through market adoption, demand realization, and achieving business objectives. Investors may view success through growth, valuation, or acquisition outcomes. Ultimately, each function participates in a relay race where success depends on effectively passing the baton to the next team.

In this thought-provoking panel discussion, participants will examine why strong science alone is not always enough, how organizational silos can undermine launch readiness, and why cross-functional alignment is often the deciding factor between commercial success and commercial disappointment.

What You’ll Learn:

• How different functions define launch success and winning.

• Common barriers that prevent organizations from achieving launch objectives despite promising therapies.

• The critical capabilities and “engines” that must operate in concert to support successful commercialization.

• Why first-time launchers face unique challenges compared to experienced commercial organizations.

• The importance of aligning around patient success while balancing commercial realities.

• Lessons learned from organizations that have successfully navigated the journey from development-stage company to commercial enterprise

Attendees will be encouraged to participate through audience polling and discussion around their own definitions of winning, creating a collaborative exchange of ideas rather than a traditional presentation.

The ultimate question explored throughout the session will be simple but powerful: When your product reaches the market, how will your organization define “winning” and what must be true to achieve it?